Candriam Luxembourg S.C.A. trimmed its position in shares of Humana Inc (NYSE:HUM) by 18.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,749 shares of the insurance provider’s stock after selling 18,062 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Humana were worth $19,535,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of HUM. Shelton Capital Management acquired a new position in shares of Humana during the second quarter worth approximately $287,000. Bank of Nova Scotia raised its position in shares of Humana by 838.2% during the second quarter. Bank of Nova Scotia now owns 32,632 shares of the insurance provider’s stock worth $7,852,000 after purchasing an additional 29,154 shares during the period. Scotia Capital Inc. raised its position in shares of Humana by 4.8% during the second quarter. Scotia Capital Inc. now owns 2,200 shares of the insurance provider’s stock worth $529,000 after purchasing an additional 100 shares during the period. Sterling Capital Management LLC acquired a new position in shares of Humana during the second quarter worth approximately $253,000. Finally, Koch Industries Inc. purchased a new stake in Humana in the 2nd quarter valued at $404,000. 94.39% of the stock is currently owned by institutional investors.

Shares of Humana Inc (NYSE:HUM) opened at $265.32 on Monday. Humana Inc has a 12-month low of $203.36 and a 12-month high of $293.35. The stock has a market capitalization of $37,903.62, a price-to-earnings ratio of 15.91, a PEG ratio of 1.54 and a beta of 0.93. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.61 and a current ratio of 1.85.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The firm had revenue of $13.19 billion during the quarter, compared to analyst estimates of $13.14 billion. During the same period last year, the firm posted $2.34 EPS. The business’s revenue was up 2.4% compared to the same quarter last year. sell-side analysts predict that Humana Inc will post 13.85 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Friday, March 30th will be given a dividend of $0.50 per share. The ex-dividend date is Wednesday, March 28th. This is a positive change from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a dividend yield of 0.75%. Humana’s dividend payout ratio (DPR) is currently 9.59%.

Humana declared that its board has authorized a stock repurchase program on Thursday, December 14th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the insurance provider to reacquire shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

A number of equities research analysts recently commented on HUM shares. BMO Capital Markets started coverage on Humana in a research report on Monday, October 16th. They issued an “outperform” rating and a $300.00 price target for the company. Zacks Investment Research lowered Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 17th. Credit Suisse Group started coverage on Humana in a research report on Thursday, November 2nd. They issued a “neutral” rating and a $256.00 price target for the company. Royal Bank of Canada reissued a “sector perform” rating and issued a $242.00 price target (down from $245.00) on shares of Humana in a research report on Thursday, November 9th. Finally, Morgan Stanley lowered their price target on Humana from $276.00 to $270.00 and set an “overweight” rating for the company in a research report on Thursday, November 9th. Eight investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Humana currently has a consensus rating of “Buy” and an average price target of $269.68.

In other news, SVP Brian P. Leclaire sold 1,679 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $245.97, for a total transaction of $412,983.63. Following the completion of the sale, the senior vice president now directly owns 9,888 shares of the company’s stock, valued at approximately $2,432,151.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Timothy S. Huval sold 1,382 shares of the firm’s stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $246.04, for a total value of $340,027.28. Following the sale, the vice president now directly owns 11,557 shares of the company’s stock, valued at $2,843,484.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,115 shares of company stock valued at $2,501,627. Insiders own 0.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://theolympiareport.com/2018/02/12/candriam-luxembourg-s-c-a-lowers-stake-in-humana-inc-hum.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.